MilliporeSigma
  • Home
  • Search Results
  • Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Thalidomide inhibits the replication of human immunodeficiency virus type 1.

Proceedings of the National Academy of Sciences of the United States of America (1993-07-01)
S Makonkawkeyoon, R N Limson-Pobre, A L Moreira, V Schauf, G Kaplan
ABSTRACT

Thalidomide, a selective inhibitor of tumor necrosis factor alpha (TNF-alpha) synthesis, suppresses the activation of latent human immunodeficiency virus type 1 (HIV-1) in a monocytoid (U1) line. The inhibition is dose dependent and occurs after exposure of the cells to recombinant TNF-alpha, phorbol myristate acetate, lipopolysaccharide, and other cytokine combinations. Associated with HIV-1 inhibition is a reduction in agonist-induced TNF-alpha protein and mRNA production. Thalidomide inhibition of virus replication in the phorbol myristate acetate- and recombinant TNF-alpha-stimulated T-cell line ACH-2 is not observed. The presence of thalidomide also inhibits the activation of virus in the peripheral blood mononuclear cells of 16 out of 17 patients with advanced HIV-1 infection and AIDS. These results suggest the use of thalidomide in a clinical setting to inhibit both virus replication and the TNF-alpha-induced systemic toxicity of HIV-1 and opportunistic infections.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(±)-Thalidomide, ≥98%, powder
Sigma-Aldrich
(−)-Thalidomide, >98%, solid
Sigma-Aldrich
(+)-Thalidomide, ≥98% (HPLC), powder